REMARKS

Claims 1-46 are pending in this application.

No new matter has been added. Any amendments to and/or cancellation of the claims was done solely to more particularly point out and distinctly claim the subject matter of Applicants' invention in order to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

Election/Restriction

The Examiner has required restriction between the following inventions in the above-identified application:

Group I: Claims 1-2, 11-23, 25-34, drawn to method of treating endometriosis using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group II: Claims 1, 3, 11-23, 25-33, 35, drawn to method of treating ovarian cancer using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group III: Claims 1, 4, 11-23, 25-33, 36, drawn to method of treating breast cancer using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group IV: Claims 1, 5, 11-23, 25-33, 37, drawn to method of treating polycystic ovary syndrome using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group V: Claims 1, 6, 11-23, 25-33, 38, drawn to method of treating uterine leiomata using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group VI: Claims 1, 7, 11-23, 25-33, 39, drawn to method of treating dysfunctional uterine bleeding using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group VII: Claims 1, 8, 11-23, 25-33, 40, drawn to method of treating premenstrual syndrome using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group VIII: Claims 1, 9, 11-23, 25-33, 41-45, drawn to method of treating vaginal bleeding using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group IX: Claims 1, 9, 11-23, 25-33, 46, drawn to method of treating uterine fibroids using LHRH antagonist and estrogen receptor modulator that is raloxifene, classified in class 514, subclass 2.

Group X: Claims 1-2, 11-22, 24, 25-34, drawn to method of treating endometriosis using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XI: Claims 1, 3, 11-22, 24, 25-33, 35, drawn to method of treating ovarian cancer using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XII: Claims 1, 4, 11-22, 24, 25-33, 36, drawn to method of treating breast cancer using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XIII: Claims 1, 5, 11-22, 24, 25-33, 37, drawn to method of treating polycystic ovary syndrome using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XIV: Claims 1, 6, 11-22, 24, 25-33, 38, drawn to method of treating uterine leiomata using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XV: Claims 1, 7, 11-22, 24, 25-33, 39, drawn to method of treating dysfunctional uterine bleeding using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XVI: Claims 1, 8, 11-22, 24, 25-33, 40, drawn to method of treating premenstrual syndrome using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XVII: Claims 1, 9, 11-22, 24, 25-33, 41-45, drawn to method of treating vaginal bleeding using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Group XVIII: Claims 1, 9, 11-22, 24, 25-33, 46, drawn to method of treating uterine fibroids using LHRH antagonist and estrogen receptor modulator that is tamoxifen, classified in class 514, subclass 2.

Applicants hereby elect, ***without traverse***, ***Group III*** (claims 1, 4, 11-23, 25-33, and 36) drawn to method of treating breast cancer using an LHRH antagonist and an estrogen receptor modulator that is raloxifene. It is Applicants' understanding that, according to the Examiner's indication, "[c]laims 1, 11-22 link(s) inventions I-XX. The restriction requirement between the linked inventions is subject to the non-allowance of the linking claim(s), claim 1, 11-22. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application".

The Examiner has also required, under 35 U.S.C. §121, an election of a single species for prosecution on the merits, to which the claims will be restricted if no generic claim is finally held to be allowable. Accordingly, within Group III, Applicants hereby further elect the species of ***the LHRH antagonist recited in claim 19*** for search purposes only. It is Applicants' understanding that upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141, *et seq.*

Applicants reserve the right to traverse the above restriction with respect to non-elected Groups I, II, IV-XX in this or subsequent applications.

SUMMARY

Applicants believe that no fee is due with this statement. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. PPI-111 from which the undersigned is authorized to draw.

Dated: February 28, 2006

Respectfully submitted,

By _____

Maria Laccotripe Zacharakis, Ph.D., J.D.
Registration No.: 56,266
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicants